Antibody-based therapy of non-Hodgkin's lymphoma

Medicine & Life Sciences

• Rituximab 100%
• Non-Hodgkin's Lymphoma 86%
• Alemtuzumab 85%
• Lymphoma, Large B-Cell, Diffuse 69%
• Monoclonal Antibodies 67%
• RFB4(dsFv)-PE38 recombinant immunotoxin 65%
• epratuzumab 55%
• Antibodies 51%
• ibritumomab tiuxetan 50%
• T-Cell Prolymphocytic Leukemia 47%
• Antibodies, Monoclonal, Humanized 39%
• Mycosis Fungoides 39%
• fludarabine 39%
• Follicular Lymphoma 37%
• Explosions 37%
• B-Cell Chronic Lymphocytic Leukemia 32%
• B-Cell Lymphoma 31%
• Combination Drug Therapy 31%
• Survival 17%
• Therapeutics 15%

Chemical Compounds

• Immunotoxin 36%